Home Cart 0 Sign in  
X

[ CAS No. 403-33-8 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 403-33-8
Chemical Structure| 403-33-8
Chemical Structure| 403-33-8
Structure of 403-33-8 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 403-33-8 ]

Related Doc. of [ 403-33-8 ]

Alternatived Products of [ 403-33-8 ]

Product Details of [ 403-33-8 ]

CAS No. :403-33-8 MDL No. :MFCD00017959
Formula : C8H7FO2 Boiling Point : -
Linear Structure Formula :- InChI Key :MSEBQGULDWDIRW-UHFFFAOYSA-N
M.W : 154.14 Pubchem ID :67878
Synonyms :

Calculated chemistry of [ 403-33-8 ]

Physicochemical Properties

Num. heavy atoms : 11
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.12
Num. rotatable bonds : 2
Num. H-bond acceptors : 3.0
Num. H-bond donors : 0.0
Molar Refractivity : 37.68
TPSA : 26.3 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.62 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.07
Log Po/w (XLOGP3) : 2.28
Log Po/w (WLOGP) : 2.03
Log Po/w (MLOGP) : 2.36
Log Po/w (SILICOS-IT) : 2.11
Consensus Log Po/w : 2.17

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.5
Solubility : 0.483 mg/ml ; 0.00314 mol/l
Class : Soluble
Log S (Ali) : -2.47
Solubility : 0.523 mg/ml ; 0.00339 mol/l
Class : Soluble
Log S (SILICOS-IT) : -2.74
Solubility : 0.282 mg/ml ; 0.00183 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.18

Safety of [ 403-33-8 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 403-33-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 403-33-8 ]
  • Downstream synthetic route of [ 403-33-8 ]

[ 403-33-8 ] Synthesis Path-Upstream   1~13

  • 1
  • [ 403-33-8 ]
  • [ 16209-00-0 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2011, vol. 21, # 19, p. 5957 - 5960
  • 2
  • [ 403-33-8 ]
  • [ 22090-24-0 ]
Reference: [1] Journal of Medicinal Chemistry, 2017, vol. 60, # 9, p. 3703 - 3726
  • 3
  • [ 403-33-8 ]
  • [ 456-06-4 ]
YieldReaction ConditionsOperation in experiment
83% With hydrazine hydrate In methanol for 5 h; Reflux General procedure: To a solution of an appropriate methyl esters17(a–j) (1.0 mmol) in 50 mL of methanol was added 99 percenthydrazine hydrate (4.0 mmol) and the mixture was refluxedfor 5 h up to reaction completed (TLC). After completionof reaction, it was allowed to cool and the obtained solidwas washed with methanol. The crude products wererecrystallized from ethanol.
80% With hydrazine hydrate In ethanol at 40℃; General procedure: Various methyl benzoate 8A-V (1.0 equiv) reacted with hydrazine hydrate (excess amount) in anhydrous ethanol. The reaction was stirred at 40 °C for overnight. The ethanol was removed under reduced pressure. The products were purified by recrystallization, which were washed with ethyl ether. The products were obtained as white solid.
75% With hydrazine hydrate In ethanol for 5 h; Reflux General procedure: Compound 12 (0.013 mol) and 80percent NH2NH2H2O (5 mL) wereadded to EtOH (10 mL), the mixturewas stirred under reflux for 5 h.After being cooled to room temperature, the precipitate was obtainedby filtration, and was dried to give the title compounds,respectively.4.1.7.1. 4-Fluorobenzohydrazide (13a). A white solid. Yield: 75percent. Mp161.9e164.4 C. 1H NMR (400 MHz, DMSO-d6) d 9.78 (s, 1H,eNHeN), 7.83e7.93 (m, 2H, ArH), 7.22e7.33 (m, 2H, ArH), 4.48 (s,2H, eNHeNH2). ESI-MS m/z: 155.1 [M H].
50% With hydrazine hydrate In ethanol for 24 h; Reflux General procedure: Various benzohydrazides 5-7 and 9-13 were obtained accordingto known procedures [40,65] except for benzohydrazides 4and 8 which were commercially available. A solution of the methylbenzoate (1 equiv) in ethanol was added dropwise to 65percent hydrazinemonohydrate (5 equiv). The reaction mixture was then heatedunder reflux and stirred overnight. The reaction progress was followedup by TLC. Crude product was collected by filtration aftercooling of the reaction medium and finally washed with coldethanol unless specified otherwise. The desired benzohydrazides were used without any further purification.The analysis of spectral data (1H and 13C NMR), the yields, HRMS,Mp and Rf of these precursors are presented in SupplementaryInformation.
280 mg Reflux General procedure: 4-fluorobenzoic acid as the raw material, methanol as a reaction solvent, a small amount of concentrated sulfuric acid catalyst, followed by stirring under heating at reflux, thin layer chromatography (TLC) to track progress of the reaction, a certain amount after the completion of the reaction NaHCO3Solution for hydrazine and the reaction liquid solution to give ester intermediate (3-1), continue to add more than the corresponding proportion of hydrazine hydrate reaction mixture was heated with stirring at reflux, thin layer chromatography (TLC) to track progress of the reaction, the reaction after completion of the reaction solution was added to a certain amount of water, then a large amount of white sink to the bottom, suction filtration to afford intermediate hydrazides (3-2)

Reference: [1] Biomedicine and Pharmacotherapy, 2017, vol. 94, p. 499 - 513
[2] Letters in Drug Design and Discovery, 2012, vol. 9, # 3, p. 276 - 281
[3] Medicinal Chemistry Research, 2016, vol. 25, # 4, p. 627 - 643
[4] European Journal of Medicinal Chemistry, 2016, vol. 120, p. 202 - 216
[5] New Journal of Chemistry, 2016, vol. 40, # 10, p. 8846 - 8854
[6] European Journal of Medicinal Chemistry, 2015, vol. 104, p. 115 - 126
[7] Arzneimittel-Forschung/Drug Research, 2001, vol. 51, # 7, p. 569 - 573
[8] European Journal of Medicinal Chemistry, 2018, vol. 159, p. 324 - 338
[9] Journal of the Indian Chemical Society, 1982, vol. 59, # 10, p. 1174 - 1176
[10] Bioorganic and Medicinal Chemistry, 2009, vol. 17, # 8, p. 3028 - 3036
[11] Zeitschrift fur Naturforschung - Section B Journal of Chemical Sciences, 2010, vol. 65, # 2, p. 178 - 184
[12] Monatshefte fur Chemie, 2010, vol. 141, # 4, p. 479 - 484
[13] Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2011, vol. 79, # 5, p. 1837 - 1842
[14] Journal of Molecular Structure, 2011, vol. 1003, # 1-3, p. 52 - 61
[15] Magnetic Resonance in Chemistry, 2011, vol. 49, # 10, p. 648 - 654
[16] Journal of Molecular Structure, 2012, vol. 1011, p. 121 - 127
[17] Journal of Agricultural and Food Chemistry, 2012, vol. 60, # 4, p. 1036 - 1041
[18] Medicinal Chemistry, 2012, vol. 8, # 6, p. 1190 - 1197,8
[19] Medicinal Chemistry, 2012, vol. 8, # 6, p. 1190 - 1197
[20] Zeitschrift fur Naturforschung - Section B Journal of Chemical Sciences, 2015, vol. 70, # 8, p. 609 - 616
[21] Medicinal Chemistry Research, 2013, vol. 22, # 3, p. 1305 - 1312
[22] Medicinal Chemistry Research, 2013, vol. 22, # 10, p. 4980 - 4991
[23] Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2013, vol. 115, p. 683 - 689
[24] Chemical Biology and Drug Design, 2013, vol. 82, # 5, p. 546 - 556
[25] Comptes Rendus Chimie, 2015, vol. 18, # 12, p. 1320 - 1327
[26] Phosphorus, Sulfur and Silicon and the Related Elements, 2016, vol. 191, # 6, p. 904 - 907
[27] Bioorganic and Medicinal Chemistry Letters, 2014, vol. 24, # 1, p. 192 - 194
[28] Medicinal Chemistry Research, 2014, vol. 23, # 4, p. 1661 - 1671
[29] Synthetic Communications, 2014, vol. 44, # 18, p. 2724 - 2737
[30] Bioorganic and Medicinal Chemistry Letters, 2015, vol. 25, # 3, p. 481 - 484
[31] Chemical Communications, 2015, vol. 51, # 76, p. 14365 - 14368
[32] Bioorganic and Medicinal Chemistry, 2016, vol. 24, # 21, p. 5611 - 5617
[33] Letters in Drug Design and Discovery, 2016, vol. 13, # 9, p. 968 - 981
[34] Journal of the Chemical Society of Pakistan, 2016, vol. 38, # 5, p. 864 - 881
[35] Patent: CN104488911, 2016, B, . Location in patent: Paragraph 0019-0020
[36] Patent: CN104488908, 2016, B, . Location in patent: Paragraph 0007; 0016; 0017
[37] Patent: CN104488909, 2016, B, . Location in patent: Paragraph 0016-0017
[38] Patent: CN104522035, 2016, B, . Location in patent: Paragraph 0016; 0017
[39] Patent: CN104542624, 2016, B, . Location in patent: Paragraph 0019; 0020
[40] Patent: CN104521990, 2016, B, . Location in patent: Paragraph 0016; 0017
[41] Chemical Biology and Drug Design, 2017, vol. 90, # 2, p. 200 - 209
[42] Patent: CN104672162, 2017, B, . Location in patent: Paragraph 0111; 0112
[43] Patent: CN104488963, 2017, B, . Location in patent: Paragraph 0026-0027
[44] Patent: CN106957242, 2017, A, . Location in patent: Paragraph 0085; 0087; 0088; 0089; 0091
[45] Patent: CN106866708, 2017, A, . Location in patent: Paragraph 0080
[46] Patent: CN104488893, 2017, B, . Location in patent: Paragraph 0036; 0037
[47] Patent: CN104488900, 2017, B, . Location in patent: Paragraph 0007; 0016-0017
[48] Patent: CN104488926, 2016, B, . Location in patent: Page/Page column 0016; 0018
[49] Bulletin of the Chemical Society of Ethiopia, 2017, vol. 31, # 3, p. 481 - 489
[50] Pharmaceutical Chemistry Journal, 2018, vol. 51, # 10, p. 907 - 917
[51] Journal of Chemistry, 2017, vol. 2017,
  • 4
  • [ 403-33-8 ]
  • [ 459-56-3 ]
  • [ 391-92-4 ]
  • [ 392-04-1 ]
Reference: [1] Organic and Biomolecular Chemistry, 2008, vol. 6, # 7, p. 1251 - 1259
  • 5
  • [ 403-33-8 ]
  • [ 392-04-1 ]
YieldReaction ConditionsOperation in experiment
78% With oxone; Ru(MesCO2)(4,4'-dibromobipyridine)(p-cymene); trifluoroacetic acid; trifluoroacetic anhydride In 1,2-dichloro-ethane at 110℃; for 8 h; Sealed tube; Green chemistry General procedure: The Ru(MesCO2)(L) (p-cymene) [L- 2,2’-bypyridine or 4,4’-dibromobipyridine] (2.5 molpercent), oxidant (2.0 eq) and ester (1.0 eq) were added to a sealed tube. Following that, trifluoroacetic acid (TFA) and trifluoroacetic anhydride (TFAA) in the ratio of 0.6 ml: 0.4 were added. The reaction mixture was kept on a pre-heated bath at 110°C and stirred until its completion. It was continuously monitored by TLC. Ice water was added to quench the reaction mixture and it was extracted with dichloromethane. The organic layer was dried over Na2SO4 and rota-evaporated. Finally the residue was purified by silica gel column chromatography to give corresponding products.
Reference: [1] Tetrahedron Letters, 2017, vol. 58, # 38, p. 3743 - 3746
  • 6
  • [ 403-33-8 ]
  • [ 459-56-3 ]
  • [ 391-92-4 ]
  • [ 392-04-1 ]
Reference: [1] Organic and Biomolecular Chemistry, 2008, vol. 6, # 7, p. 1251 - 1259
  • 7
  • [ 403-33-8 ]
  • [ 75-05-8 ]
  • [ 4640-67-9 ]
YieldReaction ConditionsOperation in experiment
83% With sodium hexamethyldisilazane In tetrahydrofuran; toluene at -5 - 0℃; Large scale Methyl 4-fluorobenzoate (29.44 kg), toluene (177 L) and acetonitrile (59 L; 5.9 mol equivalents versus methyl 4-fluorobenzoate) were charged to the reactor. The mixture was cooled to a temperature of -5 / 0 ° C. A solution of sodium bis (trimethylsilyl) amide (NaHMDS 40percent in THF) (192 L; 2 mol / mol vs. methyl 4-fluorobenzoate) was added while maintaining the temperature between -5 / + 5 ° C. The addition line was washed off with toluene (9 L). The reaction mixture was quenched by adding dilute hydrochloric acid while maintaining the temperature of -5 / + 25 ° C. The addition of acid was continued until pH <5. The layers separated and the lower aqueous layer was removed. The solvent was removed by vacuum distillation to a small amount. Toluene (59 L) was added and the mixture was heated to 85/90 ° C. to give a solution. The mixture was cooled to T = 50/55 ° C. and n-heptane (29 L) was added to obtain a precipitate. The mixture was further cooled to T = 20/25 ° C. and the solid product was isolated by filtration and washed with n-heptane (59 L). The product in the moist state was dried under vacuum at T = 40/45 ° C. to give 4-fluorobenzoylacetonitrile (26 kg, yield 83percent) of purity 98.7percent Apercent GC. The amount of 4-methoxybenzoylacetonitrile as an impurity was 0.03percent (Apercent GC).
Reference: [1] Patent: JP2018/43989, 2018, A, . Location in patent: Paragraph 0124-0131
  • 8
  • [ 403-33-8 ]
  • [ 75-05-8 ]
  • [ 456-22-4 ]
  • [ 4640-67-9 ]
YieldReaction ConditionsOperation in experiment
64% With sodium hydride In tert-butyl methyl ether; water at 90℃; Methyl 4-fluorobenzoate (50 g)Was added to a suspension of sodium hydride in methyl-tert-butyl ether (MTBE)(2 eq.) At 90 ° C.4-fluorobenzoylacetonitrile was obtained in about 64percent yield.4-fluorobenzoic acid with a purity of 81percent, 17.5percent4-methoxybenzoylacetonitrile was about 3percent
Reference: [1] Patent: JP2018/43989, 2018, A, . Location in patent: Paragraph 0129
  • 9
  • [ 288-32-4 ]
  • [ 403-33-8 ]
  • [ 101184-08-1 ]
YieldReaction ConditionsOperation in experiment
59% With potassium carbonate In dimethyl sulfoxide at 120℃; for 3 h; A mixture of imidazole (132 g, 1.9 mol), methyl 4-fluorobenzoate (170 ml, 1.3 [0385] mol) and potassium carbonate (357 g, 2.6 mol) in DMSO (200 ml)And the mixture was stirred at 120 ° C for 3 hours. After cooling to room temperature, the mixture was added to cold water. The precipitated product was filtered and washed with water. Yield: 59percent.
Reference: [1] Patent: KR101502187, 2015, B1, . Location in patent: Paragraph 0384; 0385
[2] Journal of Medicinal Chemistry, 1990, vol. 33, # 4, p. 1091 - 1097
[3] Patent: US4804662, 1989, A,
  • 10
  • [ 403-33-8 ]
  • [ 18156-74-6 ]
  • [ 420-56-4 ]
  • [ 101184-08-1 ]
Reference: [1] Journal of Organic Chemistry, 2011, vol. 76, # 4, p. 1151 - 1154
  • 11
  • [ 403-33-8 ]
  • [ 82702-31-6 ]
Reference: [1] Patent: WO2006/51390, 2006, A1, . Location in patent: Page/Page column 34-35
  • 12
  • [ 403-33-8 ]
  • [ 132813-14-0 ]
Reference: [1] Patent: JP2018/43989, 2018, A,
[2] Patent: JP2018/43989, 2018, A,
  • 13
  • [ 403-33-8 ]
  • [ 162046-66-4 ]
Reference: [1] Molecular Pharmacology, 2016, vol. 90, # 2, p. 80 - 95
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 403-33-8 ]

Fluorinated Building Blocks

Chemical Structure| 175278-29-2

[ 175278-29-2 ]

Methyl 5-fluoro-2-methylbenzoate

Similarity: 0.98

Chemical Structure| 180636-50-4

[ 180636-50-4 ]

Methyl 4-fluoro-3-methylbenzoate

Similarity: 0.98

Chemical Structure| 17449-48-8

[ 17449-48-8 ]

Dimethyl 5-fluoroisophthalate

Similarity: 0.98

Chemical Structure| 451-46-7

[ 451-46-7 ]

Ethyl 4-fluorobenzoate

Similarity: 0.96

Chemical Structure| 74733-25-8

[ 74733-25-8 ]

Methyl 3-fluoro-4-formylbenzoate

Similarity: 0.96

Aryls

Chemical Structure| 175278-29-2

[ 175278-29-2 ]

Methyl 5-fluoro-2-methylbenzoate

Similarity: 0.98

Chemical Structure| 180636-50-4

[ 180636-50-4 ]

Methyl 4-fluoro-3-methylbenzoate

Similarity: 0.98

Chemical Structure| 17449-48-8

[ 17449-48-8 ]

Dimethyl 5-fluoroisophthalate

Similarity: 0.98

Chemical Structure| 451-46-7

[ 451-46-7 ]

Ethyl 4-fluorobenzoate

Similarity: 0.96

Chemical Structure| 74733-25-8

[ 74733-25-8 ]

Methyl 3-fluoro-4-formylbenzoate

Similarity: 0.96

Esters

Chemical Structure| 175278-29-2

[ 175278-29-2 ]

Methyl 5-fluoro-2-methylbenzoate

Similarity: 0.98

Chemical Structure| 180636-50-4

[ 180636-50-4 ]

Methyl 4-fluoro-3-methylbenzoate

Similarity: 0.98

Chemical Structure| 17449-48-8

[ 17449-48-8 ]

Dimethyl 5-fluoroisophthalate

Similarity: 0.98

Chemical Structure| 451-46-7

[ 451-46-7 ]

Ethyl 4-fluorobenzoate

Similarity: 0.96

Chemical Structure| 74733-25-8

[ 74733-25-8 ]

Methyl 3-fluoro-4-formylbenzoate

Similarity: 0.96